AKRO logo

Akero Therapeutics, Inc. (AKRO) Cash From Financing

Annual CFF:

$445.85M+$92.53M(+26.19%)
December 31, 2024

Summary

  • As of today, AKRO annual cash from financing is $445.85 million, with the most recent change of +$92.53 million (+26.19%) on December 31, 2024.
  • During the last 3 years, AKRO annual cash from financing has risen by +$445.24 million (+73960.80%).
  • AKRO annual cash from financing is now at all-time high.

Performance

AKRO Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAKROcash flow metrics

Quarterly CFF:

-$34.03M-$37.46M(-1091.17%)
September 30, 2025

Summary

  • As of today, AKRO quarterly cash from financing is -$34.03 million, with the most recent change of -$37.46 million (-1091.17%) on September 30, 2025.
  • Over the past year, AKRO quarterly cash from financing has dropped by -$37.09 million (-1209.46%).
  • AKRO quarterly cash from financing is now -108.60% below its all-time high of $395.53 million, reached on March 31, 2025.

Performance

AKRO Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAKROcash flow metrics

TTM CFF:

$440.93M-$37.09M(-7.76%)
September 30, 2025

Summary

  • As of today, AKRO TTM cash from financing is $440.93 million, with the most recent change of -$37.09 million (-7.76%) on September 30, 2025.
  • Over the past year, AKRO TTM cash from financing has increased by +$70.57 million (+19.05%).
  • AKRO TTM cash from financing is now -37.47% below its all-time high of $705.10 million, reached on March 31, 2024.

Performance

AKRO TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAKROcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

AKRO Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+26.2%-1209.5%+19.1%
3Y3 Years+10000.0%-115.6%+74.2%
5Y5 Years+364.5%-116.8%+117.0%

AKRO Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high>+9999.0%-108.6%at low-37.5%+74.2%
5Y5-Yearat high>+9999.0%-108.6%at low-37.5%>+9999.0%
All-TimeAll-Timeat high>+9999.0%-108.6%at low-37.5%>+9999.0%

AKRO Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2025
-
-$34.03M(-1091.2%)
$440.93M(-7.8%)
Jun 2025
-
$3.43M(-99.1%)
$478.02M(+0.8%)
Mar 2025
-
$395.53M(+420.5%)
$474.44M(+6.4%)
Dec 2024
$445.85M(+26.2%)
$75.99M(+2377.7%)
$445.85M(+20.4%)
Sep 2024
-
$3.07M(+2144.7%)
$370.36M(+0.6%)
Jun 2024
-
-$150.00K(-100.0%)
$368.10M(-47.8%)
Mar 2024
-
$366.94M(>+9900.0%)
$705.10M(+99.6%)
Dec 2023
$353.32M(+38.2%)
$502.00K(-37.7%)
$353.32M(-0.6%)
Sep 2023
-
$806.00K(-99.8%)
$355.54M(-37.9%)
Jun 2023
-
$336.86M(+2123.0%)
$572.63M(+111.6%)
Mar 2023
-
$15.15M(+456.5%)
$270.65M(+5.9%)
Dec 2022
$255.63M(>+9900.0%)
$2.72M(-98.8%)
$255.63M(+1.0%)
Sep 2022
-
$217.90M(+524.8%)
$253.15M(+616.7%)
Jun 2022
-
$34.88M(>+9900.0%)
$35.32M(+4874.8%)
Mar 2022
-
$132.00K(-45.7%)
$710.00K(+17.9%)
Dec 2021
$602.00K
$243.00K(+252.2%)
$602.00K(+44.0%)
DateAnnualQuarterlyTTM
Sep 2021
-
$69.00K(-74.1%)
$418.00K(-99.8%)
Jun 2021
-
$266.00K(+1008.3%)
$203.13M(+0.1%)
Mar 2021
-
$24.00K(-59.3%)
$202.97M(-0.1%)
Dec 2020
$203.11M(+111.6%)
$59.00K(-100.0%)
$203.11M(-0.0%)
Sep 2020
-
$202.78M(>+9900.0%)
$203.16M(>+9900.0%)
Jun 2020
-
$100.00K(-39.0%)
-$1.23M(-101.3%)
Mar 2020
-
$164.00K(+42.6%)
$96.87M(+0.9%)
Dec 2019
$95.99M(+12.9%)
$115.00K(+107.2%)
$95.99M(-42.2%)
Sep 2019
-
-$1.61M(-101.6%)
$166.10M(-1.0%)
Jun 2019
-
$98.20M(>+9900.0%)
$167.70M(+99.0%)
Mar 2019
-
-$720.00K(-101.0%)
$84.29M(-0.8%)
Dec 2018
$85.01M(+1600.1%)
$70.22M(>+9900.0%)
$85.01M(+475.0%)
Sep 2018
-
$0.00(-100.0%)
$14.78M(0.0%)
Jun 2018
-
$14.78M(>+9900.0%)
$14.78M(>+9900.0%)
Mar 2018
-
$0.00
$0.00
Dec 2017
$5.00M
-
-

FAQ

  • What is Akero Therapeutics, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Akero Therapeutics, Inc.?
  • What is Akero Therapeutics, Inc. annual cash from financing year-on-year change?
  • What is Akero Therapeutics, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Akero Therapeutics, Inc.?
  • What is Akero Therapeutics, Inc. quarterly cash from financing year-on-year change?
  • What is Akero Therapeutics, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Akero Therapeutics, Inc.?
  • What is Akero Therapeutics, Inc. TTM cash from financing year-on-year change?

What is Akero Therapeutics, Inc. annual cash from financing?

The current annual cash from financing of AKRO is $445.85M

What is the all-time high annual cash from financing for Akero Therapeutics, Inc.?

Akero Therapeutics, Inc. all-time high annual cash from financing is $445.85M

What is Akero Therapeutics, Inc. annual cash from financing year-on-year change?

Over the past year, AKRO annual cash from financing has changed by +$92.53M (+26.19%)

What is Akero Therapeutics, Inc. quarterly cash from financing?

The current quarterly cash from financing of AKRO is -$34.03M

What is the all-time high quarterly cash from financing for Akero Therapeutics, Inc.?

Akero Therapeutics, Inc. all-time high quarterly cash from financing is $395.53M

What is Akero Therapeutics, Inc. quarterly cash from financing year-on-year change?

Over the past year, AKRO quarterly cash from financing has changed by -$37.09M (-1209.46%)

What is Akero Therapeutics, Inc. TTM cash from financing?

The current TTM cash from financing of AKRO is $440.93M

What is the all-time high TTM cash from financing for Akero Therapeutics, Inc.?

Akero Therapeutics, Inc. all-time high TTM cash from financing is $705.10M

What is Akero Therapeutics, Inc. TTM cash from financing year-on-year change?

Over the past year, AKRO TTM cash from financing has changed by +$70.57M (+19.05%)
On this page